Trials / Completed
CompletedNCT02116361
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | onabotulinumtoxinA | OnabotulinumtoxinA injected into protocol-specified areas on Day 1. |
| DRUG | Normal Saline | Placebo (normal saline) injected into protocol-specified areas on Day 1. |
Timeline
- Start date
- 2014-04-22
- Primary completion
- 2016-08-25
- Completion
- 2016-12-22
- First posted
- 2014-04-16
- Last updated
- 2017-12-19
- Results posted
- 2017-12-19
Locations
35 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02116361. Inclusion in this directory is not an endorsement.